🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "significant breakthrough" in the effort against increasingly resistant strains of the bacteria, according to researchers.

An International Health Concern

The sexually transmitted infection are increasing around the world, with estimates suggesting more than 82 million infections each year. Notably increased rates are reported in Africa and countries within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. In England, cases have hit a record high, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune step in the reality of rising global incidence, increasing antimicrobial resistance and the very limited therapeutic options currently available.”

Health officials are increasingly worried about the increase in antibiotic-resistant strains. The WHO has classified it as a "high-priority threat". A tracking program found that the effectiveness of primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Therapies Gain Approval

One new antibiotic, marketed under the name Nuzolvence, was approved by the US FDA in December for treating gonorrhoea. This STI can lead to significant complications, including infertility. Researchers believe that specific application of this new drug will help slow the spread of drug resistance.

Gepotidacin, originating from the pharmaceutical company GSK, also received approval in close succession. This treatment, which is employed against urinary tract infections, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin stemmed from a unique collaborative effort for antibiotic development. The charitable organization GARDP partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This milestone signifies a huge turning point in the treatment of multidrug-resistant gonorrhoea, which previously has been outpacing our drug pipeline.”

Testing Outcomes and Worldwide Availability

According to findings published in a prominent scientific publication, the new drug cured over nine in ten of genital gonorrhoea infections. This puts it on an equal footing with the typical regimen, which uses an injection and a pill. The research included hundreds of participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the ability to license and sell the drug in numerous developing nations.

Doctors directly involved have voiced positive views. Having a easy-to-administer therapy such as this is hailed as a "revolutionary step" for public health efforts. This is viewed as essential to alleviate the strain of the infection for patients and to prevent the spread of extremely resistant gonorrhoea worldwide.